Market LIVE
Published markets; coverage varies by country
Product profile · United States

Simponi

 ·  Patent Litigation & Settlement History ↓

Ingredientgolimumab
Application typeBLA
Application125289
Product003
Dosage formInjection
RouteSubcutaneous
Strength100MG/ML
Approval date2013-05-15
Marketing statusRx
Status event—
ApplicantJanssen Biotech, Inc.
Product source

Current GenericRadar decision

Year2021
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeEXCLUSIVITY
Anchor date2021-04-24
Patent anchor—
Exclusivity anchor2021-04-24
Protection date—
First Final ANDA—
Status event—

GNR judgment: DEEP_REVIEW. Reference year: 2021. Anchor type: EXCLUSIVITY. Patent anchor: not recorded. Exclusivity anchor: 2021-04-24. Anchor date: 2021-04-24. Patent tail: not established. Exclusivity tail: not established. Review status: FINAL. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
80173252029-01-13PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
105003482031-11-20PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
91702492032-03-12PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
98904102032-03-12PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
121397352032-07-06PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
88528892032-07-06PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
94758582032-07-06PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
116335462032-11-08PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
89568302033-03-14PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
92171682033-03-14PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
94878102033-03-14PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
96638102033-03-14PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
104219862035-08-08PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
112255162039-05-03PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
Orphan Exclusivity Exp. Date—2032-10-07————Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
761452 / 001BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2026-05-15—Accord BioPharma Inc.NREFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource
761452 / 001INTERCHANGEABILITY · INTERCHANGEABLE——Accord BioPharma Inc.NREFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource
761452 / 002INTERCHANGEABILITY · INTERCHANGEABLE——Accord BioPharma Inc.NREFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource
761452 / 002BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2026-05-15—Accord BioPharma Inc.NREFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 2 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
761452 / 001Accord BioPharma Inc.BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2026-05-15 REFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
761452 / 002Accord BioPharma Inc.BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2026-05-15 REFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
BLA_PATENT_EXCLUSIVITY_REVIEW—BUSINESS_CLASSIFICATION_WITH_CONDITIONSEnglish description not available.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.